Nuvectis Pharma (NVCT) Stock Statistics & Valuation Metrics

Nuvectis Pharma has a market cap or net worth of $153.95M. The enterprise value is $101.33M.

Nuvectis Pharma has 25,614,897 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nuvectis Pharma’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -204.33%.

The current PE Ratio of Nuvectis Pharma is ―. Nuvectis Pharma’s PEG ratio is 0.22.

In the last 12 months, Nuvectis Pharma had revenue of 0.00 and earned -19.00M in profits. Earnings per share was -1.11.

In the last 12 months, operating cash flow was -14.50M and capital expenditures 0.00, giving a free cash flow of -14.50M billion.

Nuvectis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Nuvectis Pharma upcoming earnings date is Mar 10, 2026, Before Open (Confirmed).

Nuvectis Pharma as a current ratio of 2.09, with Debt / Equity ratio of 0.00%

In the past 12 months, Nuvectis Pharma has paid 0.00 in taxes.

Nuvectis Pharma EV to EBITDA ratio is -3.90, with an EV/FCF ratio of -6.05.

Nuvectis Pharma has $35.44M in cash and marketable securities with $0.00 in debt, giving a net cash position of $35.44M billion.

Gross margin is 33.73%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Nuvectis Pharma is $15.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy